Assessing the impact of buprenorphine for opioid use disorder on infectious disease management.

Jamie Lo¹, Anusorn Thanataveerat², Amanda Manfredo³, Jennifer Falk³, Ni Zeng³, Stephanie Wall³, Taylor Ryan³, William Pratt³, Sami El-Dalati⁴, Sabrina Gaiazov¹

¹Indivior Inc., Medical Affairs, North Chesterfield, VA, United States of America.

²Veradigm Inc., Raleigh, NC, United States of America. Electronic address: Dew.Thanataveerat@veradigm.com.

³Veradigm Inc., Raleigh, NC, United States of America.

⁴University of Kentucky College of Medicine, Internal Medicine, Lexington, KY, United States of America.

PubMed DOI

Abstract

INTRODUCTION: Injection opioid misuse is associated with the transmission of infectious diseases (IDs) such as hepatitis B and C, and skin and soft tissue infections. Medications for opioid use disorder (MOUD) are effective treatments for opioid use disorder (OUD) and can reduce ID risk and improve outcomes. This study evaluated the association between treatment with buprenorphine extended-release…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.